The effectiveness of contraceptive containing estradiol valerate in combination with dienogest in patients with polycystic ovary syndrome

Pestrikova T.Iu.; Sukhonosova E.L.; Iurasova E.A.

doi:https://doi.org/10.17116/repro2016223115-122

Pestrikova T.Iu.

Kafedra akusherstva i ginekologii Dal'nevostochnogo gosudarstvennogo meditsinskogo universiteta, Khabarovsk

Sukhonosova E.L.

Dal'nevostochnyĭ gosudarstvennyĭ meditsinskiĭ universitet, Khabarovsk

Iurasova E.A.

Kafedra akusherstva i ginekologii Dal'nevostochnogo gosudarstvennogo meditsinskogo universiteta, Khabarovsk

The effectiveness of contraceptive containing estradiol valerate in combination with dienogest in patients with polycystic ovary syndrome

Authors:

Pestrikova T.Iu., Sukhonosova E.L., Iurasova E.A.

More about the authors

Journal: Russian Journal of Human Reproduction. 2016;22(3): 115‑122

DOI: 10.17116/repro2016223115-122

Read: 601 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Pestrikova TIu, Sukhonosova EL, Iurasova EA. The effectiveness of contraceptive containing estradiol valerate in combination with dienogest in patients with polycystic ovary syndrome. Russian Journal of Human Reproduction. 2016;22(3):115‑122. (In Russ.)
https://doi.org/10.17116/repro2016223115-122

Подписка 2026 Проблемы репродукции (Russian Journal of Human Reproduction)

Использование инфографики авторами научных работ

Close metadata

Abstract:

Objective - to study the therapeutic effect of hormonal contraceptive (estradiol valerate combined with dienogest) in cyclic mode in patients with polycystic ovary syndrome (hyperandrogenism + polycystic ovaries). Material and methods. 36 patients aged 22 to 31 years with symptoms of hyperandrogenism and menstrual irregularities were included in the study. Results. Hormonal contraceptive (estradiol valerate combined with dienogest), was used in continuous mode. Positive therapeutic effect on clinical manifestations of hyperandrogenism and reproductive system of patients with polycystic ovary syndrome was observed. The contraceptive effect was noticed in 100% of cases. Conclusion. The therapeutic effect of estradiol valerate combined with dienogest showed reduction of hyperandrogenism symptoms (acne, oily skin person); a statistically significant reduction in sonographic parameters of the ovaries.

Keywords:

polycystic ovary syndrome (phenotype - ovulatory dysfunction+hyperandrogenism + polycystic ovaries) hormonal contraceptive (estradiol valerate combined with dienogest)

Authors:

Pestrikova T.Iu.

Kafedra akusherstva i ginekologii Dal'nevostochnogo gosudarstvennogo meditsinskogo universiteta, Khabarovsk

Sukhonosova E.L.

Dal'nevostochnyĭ gosudarstvennyĭ meditsinskiĭ universitet, Khabarovsk

Iurasova E.A.

Kafedra akusherstva i ginekologii Dal'nevostochnogo gosudarstvennogo meditsinskogo universiteta, Khabarovsk

Close metadata

References:

Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. (2004) Revised 2003 consensus on diagnostic criteria and long-term health risks related to Polycystic Ovary Syndrome (PCOS). Hum Reprod. 2004;19:41-47.
Palep-Singh M, Mook K, et al. An observational study of Yasmin in the management of women with polycystic ovary syndrome. J Fam Plann Reprod Health Care. 2004;30:163-165.
Evidence-based Methodology Workshop on Polycystic Ovary Syndrome. 2012 December 3-5. http://prevention.nih.gov/workshops/2012/pcos/
Parke S, Nahum GG, Mellinger U, Junge W. Metabolic effects of a new four-phasic oral contraceptive containing estradiol valerate and dienogest. Obstet Gynecol. 2008;111:15S.
Endrikat J, Parke S, Trummer D, et al. Ovulation inhibition with four variations of a four-phasic estradiol valerate/dienogest combined oral contraceptive: Results of two prospective, randomized,open-label studies. Contraception. 2008;78:3:218-225.
Jensen J. Evaluation of a new estradiol oral contraceptive: estradiol valerate and dienogest. Exp Opin Pharmacother. 2010;11:1147-1157.
Okoroh EM, Hooper WC, Atrash HK, et al. Is polycystic ovary syndrome another risk factor for venous thromboembolism? United States, 2003-2008. Am J Obstet Gynecol. 2012;207:377.e1-377.e8.
Bitzer J, Amy J-J, Beerthuizen R, et al. Statement on combined hormonal contraceptives containing third- or fourth-generation progestogens or cyproterone acetate, and the associated risk of thromboembolism. Eur J Contr Reprod Health Care. 2013;0:1-4.
Junge W, Mellinger U, Parke S, Serrani M. Metabolic and haemostatic effects of estradiol valerate/dienogest, a novel oral contraceptive: a randomized, open-label, single-centre study. Clin Drug Investig. 2011;31(8):573-584.